Aurinia Pharmaceuticals Projects $315M-$325M Revenue for 2026
summarizeSummary
Aurinia Pharmaceuticals has provided its revenue guidance for 2026, projecting sales to be in the range of $315 million to $325 million. This forward-looking financial outlook is a material update for investors, setting expectations for the company's performance in the current fiscal year. This guidance follows the company's strong 2025 financial turnaround, as reported in its February 2026 10-K, which highlighted robust LUPKYNIS sales. Traders will now be comparing this guidance against existing analyst consensus estimates to gauge potential upside or downside, which could influence the stock's movement, especially as it trades near its 52-week high.
At the time of this announcement, AUPH was trading at $16.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $7.29 to $16.88. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.